{"entity":{"id":"stipple-bio","kind":"company","name":"Stipple Bio","aka":[],"tldr":"Stipple Bio looks for tiny regions on cancer-cell proteins that healthy cells do not show, then builds antibodies that bind only those regions. Its first medicine is an antibody-drug conjugate expected to start human trials in early 2027.","summary":"Stipple Bio, founded in 2022 by Aaron Ring of Fred Hutchinson Cancer Center and Aashish Manglik of UCSF, uses its Pointillist platform to find tumour-specific cell surface epitopes and design binders that recognise them, with the aim of avoiding on-target, off-tumour toxicity. Its lead candidate STP-100 is an antibody-drug conjugate incorporating tumour-specific binders, expected to enter clinical studies in early 2027; its target is undisclosed. The company emerged from stealth on 6 April 2026 with an oversubscribed USD 100 million Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest, with existing investors including Emerson Collective, GV, LoLa Capital Partners and GordonMD Global Investments. In June 2026 it took a multi-target licence from Lonza for ADC technology. Jeff Landau is chief executive.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://stipple.bio/"},{"label":"Emergence from stealth and USD 100 million Series A, April 2026","url":"https://stipple.bio/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointil/"},{"label":"Pipeline","url":"https://stipple.bio/pipeline/"},{"label":"Lonza licence, June 2026","url":"https://stipple.bio/stipple-bio-enters-multi-target-license-agreement-with-lonza-to-advance-precision-oncology-adc-therapies/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The STP-100 target and intended cancers are not disclosed. The seed round (a16z Bio+Health, Emerson Collective, OMX per trade coverage) has no stated amount or date."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://stipple.bio/","founded":2022,"stage":"startup","investors":["ra-capital","a16z-bio-health","gv"],"funding":[{"round":"Series A","year":2026,"amountUsd":100000000,"source":"https://stipple.bio/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointil/","note":"Co-led by RA Capital, a16z Bio+Health and Nextech Invest"}]},"route":"/companies/stipple-bio/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/"},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}